Photo of Dr Kate Stringaris

Dr Kate Stringaris

Telephone:

Email:

Location:

  • University College Hospital Grafton Way Building
  • University College Hospital Macmillan Cancer Centre

GMC/GDC number:

4729008

Professional background

Kate Stringaris is a consultant haematologist at University College London Hospital. She earned her medical degree from University College London and completed her general medical training at St George's Hospital. She was appointed as a senior clinical lecturer and consultant haematologist at St Bart's Hospital in London in 2014 after completing her PhD on the natural killer cell immune response to leukaemia at Imperial College London and her specialist haematology training at the Hammersmith and Royal Free Hospitals in London.

She worked as a senior research physician at the National Heart Lung and Blood Institute, National Institutes of Health in Bethesda, USA, between 2016 and 2021, where she concentrated on natural killer cell immunity, immune therapies for acute myeloid leukaemia and novel methods of stem cell transplantation.

Specialties

Research interests

Her research has focused on immune defects in leukaemia, immune therapy and transplantation immunology. She is particularly interested in the treatment of acute myeloid leukaemia and the development of innovative therapies to improve patient outcomes through clinical practice, trials and research.

She is a member of the national UK AML Research Network steering committee (previously NCRI) which meets regularly to design and refine new clinical trials in the field.

Publications

  • The Effect of the Pre-Transplant Disease Status on the Outcome for Recipients of T-Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell Lymphomas. Marzolini MAV, Kayani I, Carpenter B, Laurence A, McLornan D, Raj K, O'Reilly M, Roddie C, Stringaris K, Kottaridis P, Morris EC, Thomson KJ, Peggs KS. Eur J Haematol. 2024 Dec 11. 
  • Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Lichtenstein D, Schischlik F, Stringaris K, Shah N et al. Blood 2021 Dec 16;138(24):2469-2484. 
  • Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. El Chaer F, Borate U, Duléry R, Holtan SG, Law AD, Muffly L, Nassereddine S, Shallis RM, Stringaris K, Taylor J, Devine SM, Mohty M and Hourigan CS. Blood Advances 2021;5 (6):1757–59. Commentary on Blood Adv (2020) 4 (21): 5580–5588. 
  • Intrabone Transplantation of CD34+ cells with Optimized Delivery Does Not Enhance Engraftment in a Rhesus Macaque Model. Stringaris K, Hoyt R, Davidson-Moncada J et al. Blood Advances 2020;4(24):6148-6156. 
  • In-vivo tracking of adoptively transferred natural killer-cells in rhesus macaques using 89Zirconium-oxine cell labeling and PET imaging. Sato N, Stringaris K, Davidson-Moncada J, Reger R, Adler S, Dunbar C, Choyke P, Childs RW. Clinical Cancer Research 2020 Jun 1;26(11):2573-2581. 
  • Editorial: Should child psychiatry be more like paediatric oncology? Stringaris A, Stringaris K. J Child Psychol Psychiatry 2018;59(12):1225-1227 
  • The importance of natural killer cell immunoglobulin-like receptor mismatch in transplant outcomes. Stringaris K, Barrett AJ. Curr Opin Hematol. 2017 Nov;24(6):489-495. Review. 
  • Orphan NKs! The mystery of the self-renewing NK cells. Stringaris K. Blood. 2017 Apr 6;129(14):1890-1891. Inside Blood editorial. 
  • A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K. Blood. 2017 Feb 9;129(6):740-758.  
  • KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, Saltarrelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K. Blood. 2016 Dec 15;128(24):2819-2823 
  • Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. J Davies, K Stringaris, A J Barrett, K Rezvani. Cytotherapy 2014 Nov;16(11):1453-1466. Review. 
  • Regulatory B-Cells Are Enriched Within the IgM Memory and Transitional Subsets in Healthy Donors but Deficient in Chronic Graft-Versus-Host Disease. A Khoder, A Sarvaria, A Alsuliman, C Chew, T Sekine, N K Stringaris, K Rezvani. Blood. 2014 Sep 25;124(13):2034-45. 
  • Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in AML. Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, R Sargeant, Pavlu J, Brisley G, de Lavallade H, A Sarvaria, D Marin, Apperley J F, Barrett A J, Rezvani K. Haematologica. 2014 May;99(5):836-47 
  • Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, Mielke S, Bazeos A, Stringaris K, Ali S, Milojkovic D, Foroni L, Chaidos A, Cooper N, Gabriel I, Apperley J, Belsey S, Flanagan RJ, Goldman J, Shpall EJ, Kelleher P, Marin D, Rezvani K. Blood. 2013 Jul 11;122(2):227-38.  
  • Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Ali S, Stringaris K, Cooper N, Goldman JM, Apperley JF, Clark RE, Marin D, Rezvani K. Blood. 2012 Jul 19;120(3):697-8. 
  • Humoral and cellular immunity to primary H1N1 infection in patients with haematological malignancies following stem cell transplantation. P Garland, H de Lavallade, T Sekine, K Hoschler, S Sriskandan, P Patel, S Brett, K Stringaris, E Loucaides, K Howe, D Marin, E Kanfer, N Cooper, D Macdonald, A Rahemtulla, M Atkins, A Danga, D Milojkovic, I Gabriel, A Khoder, A Alsuliman, J Apperley, K Rezvani. Biology of Blood and Bone Marrow Transplantation. 2011;17(5):632-9.  
  • Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. H De Lavallade, P Garland, T Sekine, K Hoschler, D Marin, K Stringaris, E Loucaides, K Howe, R Szydlo, E Kanfer, D MacDonald, P Kelleher, N Cooper, A Khoder, I Gabriel, D Milojkovic, J Pavlu, J Goldman, JF Apperley, K Rezvani. Haematologica. 2011 Feb;96(2):307-14 
  • Favorable Long-Term Outcome in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for haematological malignancies. Robert Quan Le, M Bevans, B N Savani, S Mitchell, K Stringaris, E Kozanas, A John Barrett. Biol. of Blood and Bone Marrow Transplantation. 2010 Aug; 16(8):1162-70.  
  • Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a Reduced Rate of Leukaemia Relapse after HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leukaemia but not other Haematological Malignancies. K Stringaris, S Adams, M Uribe, R Eniafe, C. O. Wu, B. N. Savani, A. John Barrett. Biol. of Blood and Bone Marrow Transplantation. 2010 Sep;16(9):1257-64. 
  • Killer Immunoglobulin Receptors, Natural Killer Cells and Leukemia. Kate Stringaris. American Society of Histocompatibility and Immunogenetics Quarterly, 2009, Vol 3, No 4, pp. 106-109. Review. 
  • Misdiagnosis of refractory macrocytic anemia. K Stringaris and B Bain, Leukemia and Lymphoma, Vol 49 (11) Nov 2008: 2196-2197